ASCO 2013 - Poster: Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases

CHICAGO, IL USA ( - Presented by S. Nilsson,1 O. Sartor,2 Ø. Bruland,3 F. Fang,4A-K. Aksnes,5 P. Cislo,4 C. Parker6 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco nilsson 5038 Ra223 pain thumb

1Karolinska University Hospital, Stockholm, Sweden; 2Tulane Cancer Center, New Orleans, LA, USA; 3University of Oslo, The Norwegian Radium Hospital, Oslo, Norway; 4Bayer HealthCare, Montville, NJ, USA; 5Algeta ASA, Oslo Norway; 6The Royal Marsden NHS Foundation Trust, Sutton, UK


The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage